ArticlePloS one2025
Use peripheral blood leukocyte parameters combined with inflammatory indicators in diagnosis and severity assessment of mycoplasma pneumoniae pneumonia in children.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- MiR-128-3p serves as a diagnostic biomarker in pediatric Mycoplasma pneumoniae pneumonia.BMC pulmonary medicine · 2026Article
- Immunopathogenesis, molecular phenotyping, and host-directed interventions for severe pediatricFrontiers in cellular and infection microbiology · 2026Review
- Risk factors for severe lower respiratory tract infection among children under 5 years of age hospitalized with respiratory syncytial virus.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2025Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMycoplasma pneumoniae is a common cause of pneumonia in children over 5 years of age. Cell Population Data (CPD) is valuable for screening various diseases, including certain infections and myeloproliferative disorders, but less used in the diagnosis of children mycoplasma pneumoniae pneumonia (MPP).
aimsTo improve the diagnostic efficacy and severity assessment of MPP in children by combining CPD with inflammatory markers.
methodsThis study was conducted at the Gansu Provincial Maternity and Child-care Hospital, China. The data was accessed on 01.10.2024 for the purpose of research. A retrospective study from 01.10. 2022-01.01.2024 included three groups of children aged 5-9 years: 1) those with MPP (n = 240), of which 73 were mild, 167 were severe; 2) those with bacterial pneumonia (n = 52); and 3) those with health check-ups (n = 340). CPD indicators were measured by Sysmex XN-9000 (Kobe, Japan) hematology analyzer. Inflammatory markers included PCT (procalcitonin), LDH (lactate dehydrogenase), CK-MB (creatine kinase isoenzyme), CRP (c-reactive protein), SAA (serum amyloid A), APTT (activated partial thromboplastin time), FIB (fibrinogen). The differences and correlation of parameters between three groups were analyzed and receiver operating characteristic (ROC) analysis was performed.
resultsMost of the leukocyte parameter indices showed statistically significant differences between the MPP group and the healthy physical examination group (p < 0.05). Compared with bacterial pneumonia group, inflammatory markers were not correlated with the occurrence of MPP (p > 0.05), while LY-X and NE-WY were negatively correlated with the occurrence of MPP (p < 0.05). ROC analysis showed that the areas under the curve (AUC) for LY-X and NE-WY were 0.707 and 0.736, respectively. Additionally, LY-WY and MO-WZ are positively correlated with the severity of MPP (p < 0.05), and the AUC for MO-WZ was 0.709. Among the inflammatory markers, the AUC for SAA was 0.828, and combining SAA with MO-WZ increased the AUC to 0.861 in distinguishing mild from severe MPP.
conclusionPeripheral blood leukocyte parameters may have clinical application value for the early diagnosis and disease progression assessment of MPP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.